Castagnoli K[au] - Search Results

Year	Number of Results
1984	1
1985	3
1986	1
1987	2
1988	4
1989	1
1990	2
1992	2
1994	3
1996	2
1997	4
1998	1
1999	4
2000	2
2001	4
2002	5
2003	4
2004	1
2007	1
2023	0

1

Studies on the oxidation of 1,4-disubstituted-1,2,3,6-tetrahydropyridines.

Castagnoli N Jr, Castagnoli K, Magnin G, Kuttab S, Shang J. Castagnoli N Jr, et al. Among authors: castagnoli k. Drug Metab Rev. 2002 Aug;34(3):533-47. doi: 10.1081/dmr-120005655. Drug Metab Rev. 2002. PMID: 12214665 Review.

2

Neuroprotection by caffeine and more specific A2A receptor antagonists in animal models of Parkinson's disease.

Schwarzschild MA, Xu K, Oztas E, Petzer JP, Castagnoli K, Castagnoli N Jr, Chen JF. Schwarzschild MA, et al. Among authors: castagnoli k. Neurology. 2003 Dec 9;61(11 Suppl 6):S55-61. doi: 10.1212/01.wnl.0000095214.53646.72. Neurology. 2003. PMID: 14663012 Review.

3

Potential metabolic bioactivation pathways involving cyclic tertiary amines and azaarenes.

Castagnoli N Jr, Rimoldi JM, Bloomquist J, Castagnoli KP. Castagnoli N Jr, et al. Among authors: castagnoli kp. Chem Res Toxicol. 1997 Sep;10(9):924-40. doi: 10.1021/tx970096j. Chem Res Toxicol. 1997. PMID: 9305573 Review.

4

Tobacco leaf, smoke and smoking, MAO inhibitors, Parkinson's disease and neuroprotection; are there links?

Castagnoli K, Murugesan T. Castagnoli K, et al. Neurotoxicology. 2004 Jan;25(1-2):279-91. doi: 10.1016/S0161-813X(03)00107-4. Neurotoxicology. 2004. PMID: 14697903 Review.

5

Enzyme-catalyzed bioactivation of cyclic tertiary amines to form potential neurotoxins.

Castagnoli N Jr, Castagnoli KP, Van der Schyf CJ, Usuki E, Igarashi K, Steyn SJ, Riker RR. Castagnoli N Jr, et al. Among authors: castagnoli kp. Pol J Pharmacol. 1999 Jan-Feb;51(1):31-8. Pol J Pharmacol. 1999. PMID: 10389142 Review.

6

Studies on the in vivo biotransformation of the tobacco alkaloid beta-nicotyrine.

Liu X, Castagnoli K, Van Der Schyf CJ, Castagnoli N Jr. Liu X, et al. Among authors: castagnoli k. Chem Res Toxicol. 2000 May;13(5):336-41. doi: 10.1021/tx990124t. Chem Res Toxicol. 2000. PMID: 10813649

7

The pharmacokinetics and pharmacodynamics of atracurium in patients with and without renal failure.

Fahey MR, Rupp SM, Fisher DM, Miller RD, Sharma M, Canfell C, Castagnoli K, Hennis PJ. Fahey MR, et al. Among authors: castagnoli k. Anesthesiology. 1984 Dec;61(6):699-702. doi: 10.1097/00000542-198412000-00011. Anesthesiology. 1984. PMID: 6239574 Free article.

8

Metabolic bioactivation reactions potentially related to drug toxicities.

Castagnoli N Jr, Castagnoli KP. Castagnoli N Jr, et al. Among authors: castagnoli kp. NIDA Res Monogr. 1997;173:85-105. NIDA Res Monogr. 1997. PMID: 9260185 Review. No abstract available.

9

Studies on the molecular mechanism of bioactivation of the selective nigrostriatal toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

Chiba K, Peterson LA, Castagnoli KP, Trevor AJ, Castagnoli N Jr. Chiba K, et al. Among authors: castagnoli kp. Drug Metab Dispos. 1985 May-Jun;13(3):342-7. Drug Metab Dispos. 1985. PMID: 2861994

10

Metabolic studies on haloperidol and its tetrahydropyridine analog in C57BL/6 mice.

Van der Schyf CJ, Castagnoli K, Usuki E, Fouda HG, Rimoldi JM, Castagnoli N Jr. Van der Schyf CJ, et al. Among authors: castagnoli k. Chem Res Toxicol. 1994 May-Jun;7(3):281-5. doi: 10.1021/tx00039a002. Chem Res Toxicol. 1994. PMID: 8075357

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results